AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02183987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Knowledge Translation Intervention
Description: 1. Access to CSN guidelines, \& provider- \& patient-directed infographics recommending an intent-to-defer dialysis initiation strategy will be displayed in prominent clinic wall space \& disseminated to patients.~2. Educational whiteboard video will be made available as a resource for clinic staff \& patients.~3. Each clinic will receive reports from the Canadian Organ Replacement Register (CORR) outlining the proportion of patients followed by a Nephrologist (>3 months) starting dialysis early (eGFR >10.5 ml/min), for all incident dialysis patients from the clinic, with provincial \& national average comparisons. These reports, \& the CSN guideline on timing of dialysis initiation recommendation, will be delivered to the medical lead for each CKD clinic.~4. Each clinic will receive an in-person visit from one of the study investigators/collaborators highlighting the clinical practice guidelines \& evidence supporting an intent-to-defer strategy, \& will receive follow-up.
Study NCT02077166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Study NCT02977780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temzolomide capsules
Study NCT02977780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Temzolomide capsules
Study NCT02977780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib tablets
Study NCT02977780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBS10072S
Description: QBS10072S administered intravenously
Study NCT01026116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 75 mg/m2 every-3-week for four cycles
Study NCT01026116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 75 mg/m2 every-3-week for four cycles
Study NCT01026116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2 every-3-week for four cycles
Study NCT01026116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 every-3-week for four cycles
Study NCT01026116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m2 every-3-week for four cycles followed by weekly paclitaxel (80 mg/m2) for 12 weeks
Study NCT01026116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2 every-3-week for four cycles followed by weekly paclitaxel (80 mg/m2) for 12 weeks
Study NCT02101554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ages 7-11
Description: Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
Study NCT02077166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT02077166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT03827122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: Experimental group we will use BTX-A administration group. All patients (Male/Female) with bruxism associated with chronic pain in masseter muscles bilaterally Patients will have treatment with 20 units of BOTOX, (Allergan Inc.) per side will be injected at three points into masseter muscle bilaterally.
Study NCT01261338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: olestra
Description: non-absorbable dietary fat
Study NCT01261338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olestra
Description: non-absorbable dietary fat
Study NCT02101554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ages 12-17
Description: Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
Study NCT03503266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] MT-7117
Description: 14-C MT-7117
Study NCT02190539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Description: Remedies are sold over the counter without a physician prescription (approved by the Israeli Ministry of Health). No toxicity or side effects are expected to be observed, potencies (dilutions) of substances beyond 7C (7 dilutions, each 1:100) do not contain a sufficient number of molecules of the original material to be pharmacologically active. Since the remedies being used in this trial are diluted at 30c and 200c, levels that are way beyond Avogrado's number, so no original material is expected to be found. This fact was verified utilizing high pressure liquid chromatography (HPLC) method. Due to those facts, most scientists do not accept that these remedies have any biological effects and consign any positive response to the placebo effect.
Study NCT04598867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-008-0045
Description: CD-008-0045 20 mg capsules
Study NCT04598867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT04598867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afobazol
Description: Afobazol 10 mg tabletes
Study NCT01515748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (XRP6976)
Description: Pharmaceutical form:solution for infusion Route of administration: intravenous
Study NCT01515748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (SR96669)
Description: Pharmaceutical form:solution for infusion Route of administration: intravenous
Study NCT01515748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT01515748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT04250181 — intervention group
Intervention type: OTHER
Intervention: RF ablation of atrial fibrillation
Description: Comparison of standard, 40W and 50W RF energy setting for ablation of atrial fibrillation
Study NCT03538834 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cod meal from residual material
Description: Cod meal from residual material, 8 g protein daily for 8 weeks
Study NCT03538834 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo
Study NCT02126579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PolyICLC
Description: 1 mL administered half intradermally and half subcutaneously
Study NCT02126579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resiquimod
Description: 500 mg applied to vaccine site after vaccine administration
Study NCT02126579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IFA
Description: 2 mL administered half intradermally and half subcutaneously
Study NCT01398618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-month rifampin vs. 9-month isoniazid
Description: In the 4M-RMP group, enrolled subjects received 600 mg rifampin daily for 4 months. In the 9M-INH group, enrolled subjects received 300 mg isoniazid daily for 9 months.
Study NCT01398618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4-month rifampin vs. 9-month isoniazid
Description: In the 4M-RMP group, enrolled subjects received 600 mg rifampin daily for 4 months. In the 9M-INH group, enrolled subjects received 300 mg isoniazid daily for 9 months.
Study NCT00675012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: iv 0.8 or 45 mcg/sqm q3W
Study NCT00675012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: iv q3W 100 mg/sqm 60 minutes after NGR-hTNF infusion
Study NCT00675012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: orally 825 mg/sqm 2qDx14
Study NCT01333046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen-Escalation Stage
Description: Antigen-Escalation Stage~Each patient will receive 2 injections at the same dose (5 x 10\^6 cells/m2), 28 days apart, according to the following schedules:~Schedule One:~* Day 0: PRAME-specific T cells~* Day 28: PRAME- and SSX-specific T cells~Schedule Two:~* Day 0: PRAME- and SSX-specific T cells~* Day 28: PRAME/SSX/MAGE-specific T cells~Schedule Three:~* Day 0: PRAME/SSX/MAGE-specific T cells~* Day 28: PRAME/SSX/MAGE/NY-ESO specific T cells~Schedule Four:~* Day 0: PRAME/SSX/MAGE/NY-ESO specific T cells~* Day 28: PRAME/SSX/MAGE/NY-ESO/Survivin-specific T cells
Study NCT01333046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose-Escalation Stage
Description: Dose-Escalation Stage~Three different dosing schedules will be evaluated. Each patient will receive 2 injections at the same dose, 14 days apart, according to the following dosing schedules:~DL1: Day 0 and Day 14: 5 x 10\^6 cells/m\^2~DL2: Day 0 and Day 14: 1 x 10\^7 cells/m\^2~DL3: Day 0 and Day 14: 2 x 10\^7 cells/m\^2
Study NCT01333046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: azacytidine and multiTAA T cells Stage
Description: Up to 15 patients will be treated with 3 cycles of aza at a dose of 75 mg/m2 I.V. administered for 5 days/cycle followed, within 28 days of the last aza dose, by two infusions (on Day 0 and Day 14) of multi-TAA specific CTLs at a fixed dose of 1x10\^7 cells/m2. If drug-related myelosuppression occurs aza dosing will be modified, according to the following:~1. ANC >1,000 or Platelets >50,000 (or any other grade I AE attributable to aza)~   Adjustment: None~2. ANC 500-1000 or Platelets 25,000-50,000 (or any other grade II-III AE attributable to aza)~   Adjustment: 50% dose reduction~3. ANC \<500 or any episode of febrile neutropenia or platelets \<25,000 or any episode of bleeding attributed to thrombocytopenia (or any other grade IV or higher AE attributable to aza)~Adjustment: Discontinue drug, can proceed with CTL infusion if eligible within 28 days of last aza infusion
Study NCT01333046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediatric multiTAA T cells Stage
Description: Patients \< 18 years old will receive two infusions (on Day 0 and Day 14) of multi-TAA specific T cells at a fixed dose of 1x10\^7 cells/m2. We will enroll and infuse at least 5 adolescents on the pediatric arm before opening to all patients.
Study NCT06094725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant
Description: Relacorilant 300 mg (3 X 100 mg softgel capsules) for oral administration
Study NCT03001284 — intervention group
Intervention type: OTHER
Intervention: NO intervention
Study NCT01811082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme A
Description: Coenzyme A 400mg per day.
Study NCT01811082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantethine
Description: Pantethine 600mg per day.
Study NCT00553696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
Study NCT00553696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 80 mg/m2 on days 1-21 of each 28 day cycle
Study NCT00553696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 25 mg, 37.5 mg and 50 mg daily S-1 80 mg/m2 on days 1-21 of each 28 day cycle Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
Study NCT02603081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPI-1005
Description: Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.
Study NCT03903484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deprescribing toolbox and intervention
Description: Pharmacist-led deprescribing plan with the patient which will include the patient's deprescribing goals. The intervention advocates for deprescribing according to recognized algorithms and guidelines which will be included in a resource toolbox/website.
Study NCT03538756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walkasins
Description: Walkasins® consist of two parts for each leg: the Haptic Module (leg unit) and the Receptor Sole (foot pad). The Haptic Module wraps around the lower leg of the user and contains electronics for reading Receptor Sole pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.
Study NCT03995069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3D
Description: Practice generating grip force to the target shown on the computer screen in 3 dimensions.
Study NCT02603081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SPI-1005
Description: Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.
Study NCT01485042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib and TH-302
Description: Pazopanib 800 mg daily TH-302 IV on Days 1, 8, 15 at MTD Subjects will receive this regimen until disease progression.
Study NCT03757000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-20394
Description: YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.
Study NCT02446301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bain®
Description: Nalbuphine HCl 20mg, IM injection
Study NCT02446301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDE
Description: Sebacoyl Dinalbuphine Ester 150mg/2ml, IM injection
Study NCT03816774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG split-dose and simethicone
Description: Patients in active comparator arm are instructed to take 250mg simethicone pill 15 minutes before PEG dose on the previous evening plus 250mg simethicone pill 15 minutes before PEG dose ending 3 hours before colonoscopy
Study NCT01826864 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC
Study NCT01826864 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node biopsy
Description: Undergo sentinel lymph node biopsy
Study NCT01826864 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sentinel lymph node biopsy
Description: Undergo sentinel lymph node biopsy
Study NCT01826864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01826864 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01826864 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypertonic saline
Description: Given SC
Study NCT03511833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: IV morphine -0.1 mg/kg: Morphine vial contains 10 mg/10 ml = 1mg/ml ----> 0.1 ml/kg
Study NCT03511833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: IN ketamine: 1 mg/kg: Ketamine vial contains 100 mg/2 ml = 50mg/ml ---> 0.02ml/kg
Study NCT01105611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400mg orally twice daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.
Study NCT01105611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir/Ritonavir
Description: Atazanavir 300mg orally once daily boosted with Ritonavir orally 100mg once daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.
Study NCT01814969 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperfractionated Radiochemotherapy
Description: 28 x 1.5Gy 2 times a day; gap between the fractions min. 6-8h - duration of treatment 2.5 weeks + simultaneous bolus 5-Fluorouracil (the each cycle consisted of 5-fluorouracil 325 mg/m2 per day) on 1-3 and 16-18 (last 3 days of radiotherapy).
Study NCT01814969 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hyperfractionated Radiotherapy
Description: 28 x 1.5Gy 2 times a day; gap between the factions min. 6-8h - duration of treatment 2.5 weeks
Study NCT00737555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHR-2797
Description: Oral once daily administration of capsules of CHR-2797, to determine safety and tolerability in patients being treated with paclitaxel infusion every 3 weeks for up to 18 weeks.
Study NCT04636970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home training program
Description: Subjects randomized to the IG will participate at home training program that will last 12 weeks and consists of endurance, flexibility, balance and cardiovascular resistance training performed with low to moderate intensity, in 20-60 minutes sessions, five times a week. Study participants will be asked to wear wrist and chest unobtrusive devices during active day time or at least during the training session and two hours before and after.
Study NCT03830593 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Adrenalectomy
Description: minimally invasive lateral transperitoneal adrenalectomy
Study NCT03995069 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 1D
Description: Practice generating grip force to the target shown on the computer screen in 1 dimension.
Study NCT04877392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lavender essential oil
Description: Use of inhaled lavender essential oil
Study NCT03393442 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain MRI scan
Description: Diagnostic brain MRI scan with the purpose to detect signal changes due to brain deposits of Gd.
Study NCT01112579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic PrimeADVANCED Neurostimulator
Description: Heart failure therapy
Study NCT01112579 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic PrimeADVANCED Neurostimulator
Description: Medical management
Study NCT00680602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavior Therapy
Description: Structured protocol described by Cordioli et al., 2003
Study NCT03144713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
Study NCT03144713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
Study NCT03144713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.
Study NCT03393442 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Brain MRI scan
Description: Diagnostic brain MRI scan with the purpose to detect signal changes due to brain deposits of Gd.
Study NCT05937113 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RABIVAX-S
Description: 1 ml dose vaccine containing ≥ 2.5 IU of purified rabies antigen (Pitman-Moore rabies virus strain 3218; acclimatized and cultured on vero cells, inactivated with β propiolactone).~Pre-exposure prophylaxis regimens for two groups~* Intramuscular 1ml on days D0, D7 and D21+7~* Intradermal injection 0.1 ml on days D0, D7 and D21+7 Blood samples were collected on days D0, D7 and D21 - 28
Study NCT01987284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SER100
Study NCT01987284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER100
Study NCT01987284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04245878 — intervention group
Intervention type: OTHER
Intervention: gastric ultrasound
Description: gastric ultrasound for measurement of the antral area
Study NCT03900702 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gaze-driven training games
Description: Training games are played on a PC with attached eye-tracker. Games include embedded training principles to improve attentional control including resistance to distraction and inhibitory control.
Study NCT03677713 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No nasal packing.
Description: No nasal packing at the end of the surgery
Study NCT03677713 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Packing
Description: Patients will have nasal packing at the end of the surgery